Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2017-04-21 | Vernalis (UK) Tris Pharma (USA - NJ) | cough | Refusal of a Market Autorisation in the US | |
0000-00-00 | assay service for understanding the impact of point mutations on protein therapeutic activity | ProImmune (UK) | Product launch | |
2018-09-15 | fremanezumab | Teva Pharmaceuticals (Israel) | migraine | Granting of a Market Authorisation in the US |
2017-12-13 | (infliximab-qbtx) | Pfizer (USA - NY) |
|
Granting of a Market Authorisation in the US |
2018-09-28 | cemiplimab | Regeneron Pharmaceuticals (USA - NY) Sanofi (France) |
|
Granting of a Market Authorisation in the US |
0000-00-00 | Granting of the orphan status in the US | |||
2017-11-16 | human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule (MAdCAM) | Shire (UK - USA) |
|
Granting of the orphan status in the US |
2017-12-19 | software | Shire (UK - USA) | hemophilia A | Granting of a Market Authorisation in the US |
2017-08-22 | Orchard Therapeutics (UK) | adenosine deaminase severe combined immunodeficiency (ADA-SCID) | Granting of a Fast Track status | |
2016-10-30 | gemcabene | Gemphire Therapeutics (USA - Mkch) | severe hypertriglyceridemia (SHTG) | Granting of a patent |
2017-10-16 | synthetic cyclic 8 amino acid analogue of human unacylated ghrelin | Alize Pharma (France) | Prader-Willi syndrome | Granting of the orphan status in the EU |
2017-12-21 | apalutamide | Janssen Biotech, a J&J company (USA - NJ) | non-metastatic castration-resistant prostate cancer (CRPC) | Submission of a Market Application in the US |
2017-11-16 | sunitinib | Pfizer (USA - NY) | treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy | Granting of a Market Authorisation in the US |
2017-12-12 | tofacitinib | Pfizer (USA - NY) | Submission of a Market Application in the US | |
2017-12-21 | angiotensin II | La Jolla Pharmaceutical (USA - CA) |
|
Granting of a Market Authorisation in the US |
2017-12-21 | avelumab in combination with Inlyta® (axitinib) | Merck KGaA (Germany) Pfizer (USA - NY) | naïve patients with advanced renal cell carcinoma (RCC) | Granting of the Breakthrough Therapy status |
2017-10-16 | Miraca Life Sciences (USA - CA) | Product launch | ||
2017-12-20 | solriamfetol | Jazz Pharmaceuticals (Ireland) | excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA) | Submission of a Market Application in the US |
2018-01-30 | pegunigalsidase alfa (alpha-galactosidase-A) | Protalix BioTherapeutics (Israel) | Fabry disease | Granting of a Fast Track status |
2017-08-31 | Patent infringement lawsuit |
© 2024 Biopharmanalyses - Powered by Samacom+